financetom
Business
financetom
/
Business
/
Noble Q1 Adjusted Earnings, Revenue Increase; 2024 Outlook Reaffirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Noble Q1 Adjusted Earnings, Revenue Increase; 2024 Outlook Reaffirmed
May 6, 2024 2:27 PM

05:09 PM EDT, 05/06/2024 (MT Newswires) -- Noble (NE) reported Q1 adjusted earnings Monday of $0.45 per diluted share, up from $0.19 a year earlier.

Analysts surveyed by Capital IQ expected $0.44.

Operating revenue for the quarter ended March 31 was $637.1 million, up from $610.1 million a year earlier.

Analysts surveyed by Capital IQ expected $587.1 million.

The firm reaffirmed its full-year 2024 revenue outlook in the range of $2.55 billion to $2.70 billion. Analysts surveyed by Capital IQ expect $2.65 billion.

The board set an interim quarterly dividend of $0.40 per share, payable June 27 to shareholders of record June 6.

Price: 46.28, Change: +0.23, Percent Change: +0.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
Nov 20, 2025
Vanda Pharmaceuticals Inc. ( VNDA ) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induced by Novo Nordisk A/S ( NVO ) Wegovy. • Get the market research on VNDA stock here. The trial studied 116 healthy overweight or obese adults. The study saw 29.3% of tradipitant-treated participants (17/58)...
Cemtrex to Acquire Invocon for $7.06 Million
Cemtrex to Acquire Invocon for $7.06 Million
Nov 20, 2025
01:59 PM EST, 11/20/2025 (MT Newswires) -- Cemtrex ( CETX ) said Thursday it has agreed to acquire Invocon, a Texas-based aerospace and defense engineering firm, for $7.06 million. The deal, which is subject to customary closing conditions, is expected to close on or around Jan. 1, 2026, the company said. After the acquisition closes, Cemtrex ( CETX ) plans...
Medexus Pharmaceuticals to Launch Normal Course Issuer Bid
Medexus Pharmaceuticals to Launch Normal Course Issuer Bid
Nov 20, 2025
01:58 PM EST, 11/20/2025 (MT Newswires) -- Medexus Pharmaceuticals ( MEDXF ) on Thursday said it received exchange approvals to launch a normal course issuer bid (NCIB).. The company may buy back for cancellation up to 2.98-million shares, about 10% of the public float. As of Nov. 12, the company had 32.4-million shares outstanding and a public float of 29.8-million...
Provident Healthcare Partners Advises Meperia in its Acquisition by Diversis Capital
Provident Healthcare Partners Advises Meperia in its Acquisition by Diversis Capital
Nov 20, 2025
BOSTON, Nov. 20, 2025 /PRNewswire/ -- Provident Healthcare Partners (Provident), a leading healthcare investment banking firm, is pleased to announce it has advised Meperia, a supply chain and strategic sourcing platform serving Integrated Delivery Networks (IDNs). Provident also facilitated Diversis in the acquisition of Kermit, a bill-only, spend management, and analytics platform for physician preference items (PPI). This transaction marks...
Copyright 2023-2026 - www.financetom.com All Rights Reserved